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Introduction: Brugada syndrome (BrS) is an inherited arrhythmia syn-
drome with increased risk of syncope and sudden death. The typical ECG pat-
tern of ST-segment elevation in the right precordial leads can fluctuate.
Sodium channel blockers, such as ajmaline or flecainide, are used to unmask
the diagnostic ECG pattern of BrS in case of non-diagnostic basal ECG. There
is no direct comparison of the electrocardiographic modification induced by
these drugs in patients under the age of 15 years. The aim of this study is to
relate our experience in our reference centre.
Methods: Injections are performed by continuous infusion over a period of
10 minutes at 1mg/kg dose for ajmaline and 2 mg/kg for flecainide. Tests were
performed in case of absence of type 1 aspect on the resting ECG and in
absence of major conduction defects.
Results: The flecainide test (group F) was performed in 36 patients and
ajmaline test (group A) in 11 patients. Mean age was 12±4 years in group F
and 14±2 years in A (p=0.04). There was 14 girls in group F (39%) vs 4 in
group A (36%), NS. All patients were in sinus rhythm in both groups. There
was no difference between the two groups for heart rate 78±21 vs 72±15 bpm
(p=0.35), PR 148±28 ms vs 138±22 ms (p=0.32), QRS 87±11 ms vs 91+/-
10 ms (p=0.29) and QTc 412±40 vs 425±30 ms (p =0.31). During the test, HR
increase in both groups 9±12 vs 6±7 bpm (p=0.52). There was no difference
for PR 31±27 ms vs 32±22 ms (p=0.89). The QRS and QTc were slightly
higher in F group (QRS 25±23 ms vs 13±12 ms, p=0.11 and QTc 32±40 vs
18±15 ms, p=0.25) even if the difference was not significant. The number of
positive tests F 11/36 (31%) vs 3/11 (27%) were similar in both groups.
During pharmacological test no arrhythmic complications has been observed.
Conclusion: In patients under the age of 15 years and suspected of BrS,
the results of Flecainide and Ajmaline challenge are similar for conduction
parameters and positive results. The risk of ventricular arrhythmias appears
very low.
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Introduction: Brugada syndrome (BrS) is an inherited arrhythmia syn-
drome with an increased risk of syncope and sudden death. There is no report
of BrS in people aged 65 years old or more. The aim of this study is to
describe the clinical characteristics of BrS in elderly people.
Methods: BrS patients older than 65 years were recruited from 8 french
tertiary centers. Clinical data investigation of family history, 12-lead ECG and
results of pharmacological challenge were collected. Average follow-up was
78±48 months.
Results: 54 patients were recruited (mean age 69±4 years), 33/54 patients
(61%) were male. The circumstances of diagnoses were: systematic ECG
(n=23, 43%), symptoms (n=19, 35%) and familial screening (n=11, 20%).
25 patients (46%) were symptomatic: resuscitated sudden cardiac death (SCD)
in 1 patient (1.8%), 12 syncope (22%), 3 supraventricular tachycardia (6%),
6 palpitation (11%) and 9 lipothymia (17%). 15 patients have history of
familial SCD (28%). Implantable cardiac defibrillator (ICD) was implanted in
15/54 patients (28%) and 1 patient (1.8%) was implanted with pacemaker. At
baseline, mean HR was 68±14 bpm, PR 190±50 mm, QRS 105±16 mm and
QTc 422±43 mm. 29 patients (54%) have spontaneous type-1 ECG. Mean ST
elevation were 3.4±1.5 mm. During follow-up only 1/54 patients (1.8%) has
an arrhythmic event. This patient was symptomatic (syncope). 2 patients died
but their death was not due to a cardiac cause. We compared our results to the
patients aged under 65 years old of the FINGER BrS Registry (n=945
patients). The number of ICD implanted patients was higher in FINGER
cohort (28 vs 42%). Patients of the FINGER cohort presented more
arrhythmic events than patients aged 65 years or more in this study (5.2 vs
1.8%).
Conclusion: Patients aged more than 65 years old seem to represent a
lower-risk group than patients aged under 65 years old. Further studies are
needed in this population in order to identify risk factors in BrS patients aged
more than 65 years old.
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Introduction: Brugada syndrome (BrS) is an inherited arrhythmia syn-
drome with increased risk of syncope and sudden death. Disease manifestation
is clearly predominant in males and the studied population mainly consisted in
men. The aim of this study is to describe the clinical characteristics of BrS in
women.
Methods: BrS women were recruited from 12 french tertiary centers. Clin-
ical data, investigation of family history, 12-lead ECG and results for pharma-
cological challenge were collected. Average follow-up was 79±52 months.
Results: 202 women were recruited (mean age 46±16 years). Circum-
stances of diagnoses were: familial screening (n=94, 47%), systematic ECG
(n= 61, 30%) and symptoms (n=47, 23%). 69 patients (34%) were symptom-
atic: resuscitated sudden cardiac death (SCD) in 11 women (5%), 42 syncope
(21%), 8 supraventricular tachycardia (4%), 21 palpitations (10%), 24 lipo-
thymia (12%) and 7 pain (3%). 20 women (10%) have a history of familial
SCD. Implantable cardiac defibrillator (ICD) was implanted in 44/202 patients
(22%). At baseline, mean HR was 71±12 bpm, PR 174±32 mm, QRS
99±17 mm and QTc 419±29 mm. 59 women (29%) have a spontaneous type-
1 ECG. Mean ST elevation were 3.3±1.1 mm. During follow-up, 7/202
patients (3.5%) have an arrhythmic event: resuscitated SCD (n=1), syncope
(n=3), ventricular arrhythmia (n=1) and appropriate ICD shock (n=2). Among
them, 5 women were symptomatic (syncope) and 2 were asymptomatic.
Asymptomatic women don’t have a spontaneous type-1 ECG at baseline
whereas 3/5 symptomatic women have a type-1 ECG at baseline. We com-
pared our results to the men of the FINGER BrS Registry (n=745). The
number of ICD implanted patients was higher in FINGER cohort (22 vs 47%).
Men of the FINGER cohort presented more arrhythmic events than women of
this study (5.7 vs 3.5%).
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